X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (144) 144
life sciences & biomedicine (120) 120
humans (108) 108
cardiovascular system & cardiology (69) 69
female (58) 58
cardiac & cardiovascular systems (57) 57
male (57) 57
middle aged (52) 52
cardiovascular (48) 48
hypercholesterolemia (47) 47
cholesterol, ldl - blood (39) 39
risk factors (37) 37
statins (37) 37
double-blind method (36) 36
treatment outcome (36) 36
aged (34) 34
anticholesteremic agents - therapeutic use (33) 33
drug therapy, combination (32) 32
hypercholesterolemia - drug therapy (32) 32
cholesterol (31) 31
ezetimibe (29) 29
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (29) 29
lipids (29) 29
astrophysics (28) 28
cardiovascular disease (28) 28
adult (27) 27
cardiology and cardiovascular medicine (27) 27
care and treatment (27) 27
low density lipoproteins (27) 27
peripheral vascular disease (27) 27
high energy astrophysical phenomena (25) 25
life sciences (25) 25
hypolipidemic agents - therapeutic use (24) 24
pharmacology & pharmacy (24) 24
physics (24) 24
pcsk9 (23) 23
physical sciences (23) 23
hyperlipidemias - drug therapy (22) 22
internal medicine (22) 22
astronomy & astrophysics (21) 21
alirocumab (20) 20
drug therapy (20) 20
physics - high energy astrophysical phenomena (20) 20
simvastatin - therapeutic use (19) 19
azetidines - therapeutic use (18) 18
cardiovascular diseases - prevention & control (18) 18
sciences of the universe (18) 18
fenofibrate - therapeutic use (17) 17
ldl-c (17) 17
abridged index medicus (16) 16
general & internal medicine (16) 16
hypercholesterolemia - blood (16) 16
hyperlipoproteinemia type ii - drug therapy (16) 16
medicine, general & internal (16) 16
simvastatin (16) 16
cardiology (15) 15
cardiovascular diseases (15) 15
diabetes (15) 15
low density lipoprotein (15) 15
astrophysics - high energy astrophysical phenomena (14) 14
cholesterol, hdl - blood (14) 14
human health and pathology (14) 14
[phys.astr.he]physics [physics]/astrophysics [astro-ph]/high energy astrophysical phenomena [astro-ph.he] (13) 13
antibodies, monoclonal - therapeutic use (13) 13
dyslipidemias - drug therapy (13) 13
health aspects (13) 13
lipids - blood (13) 13
[sdu.astr.he]sciences of the universe [physics]/astrophysics [astro-ph]/high energy astrophysical phenomena [astro-ph.he] (12) 12
anticholesteremic agents - adverse effects (12) 12
atherosclerosis (12) 12
azetidines - administration & dosage (12) 12
familial hypercholesterolemia (12) 12
statin (12) 12
triglycerides (12) 12
triglycerides - blood (12) 12
analysis (11) 11
anticholesteremic agents - administration & dosage (11) 11
apolipoproteins b - blood (11) 11
biomarkers - blood (11) 11
cardiovascular diseases - etiology (11) 11
drug combinations (11) 11
emission (11) 11
endocrinology & metabolism (11) 11
fenofibrate (11) 11
fenofibrate - administration & dosage (11) 11
genetic aspects (11) 11
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (11) 11
hyperlipoproteinemia type ii - genetics (11) 11
hypolipidemic agents - administration & dosage (11) 11
hypolipidemic agents - adverse effects (11) 11
monoclonal antibodies (11) 11
research (11) 11
safety (11) 11
time factors (11) 11
adolescent (10) 10
clinical trials (10) 10
dosage and administration (10) 10
fenofibrate - adverse effects (10) 10
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (10) 10
azetidines - adverse effects (9) 9
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cardiovascular diabetology, ISSN 1475-2840, 06/2019, Volume 18, Issue 1, pp. 1 - 20
Journal Article
The New England journal of medicine, ISSN 1533-4406, 04/2015, Volume 372, Issue 16, pp. 1489 - 1499
Journal Article
Journal Article
European heart journal, ISSN 0195-668X, 2015, Volume 36, Issue 43, pp. 2996 - 3003
Journal Article
Expert review of cardiovascular therapy, ISSN 1477-9072, 05/2012, Volume 10, Issue 5, pp. 565 - 575
Pravafenix ® is a fixed-dose combination of pravastatin 40 mg and fenofibrate 160 mg. The rationale for the use of Pravafenix is based on the increased... 
fenofibrate | Pravafenix | pravastatin | mixed hyperlipidemia | Fenofibrate | Usage | Hyperlipidemia | Dosage and administration | Research | Drug therapy, Combination | Drug therapy | Pravastatin | Health aspects
Journal Article
Journal Article
Journal Article
Journal Article